Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable. Note: The chronological list does not include December approvals. 1. Dupixent (dupilumab ...

Dupixent (dupilumab), a drug already used to treat atopic dermatitis and asthma, became the first biologic approved for chronic obstructive pulmonary disease (COPD) last fall. Most COPD treatments ...

Chronic obstructive pulmonary disease (COPD) makes it hard to breathe. Narrowed airways can make you cough, wheeze, and feel short of breath. It can affect how you exercise, work, and do other daily ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

Certain glucose-lowering drugs were linked to fewer moderate or severe COPD exacerbations in adults with type 2 diabetes Study: Glucose-Lowering Medications and Risk of Chronic Obstructive Pulmonary ...

Recent medical research reveals promising developments in the treatment of patients suffering from both diabetes and chronic obstructive pulmonary disease. The study, involving nearly 394,000 adults, ...

Biologic medicines are making inroads into chronic obstructive pulmonary disease (COPD), with two blockbuster antibodies expanding their FDA-approved uses to this lung disorder in the past year. A ...